AMRX Q3 2021 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$529M+1.8% YoY

Gross Profit

$199M37.6% margin

Operating Income

$29M5.4% margin

Net Income

-$4M-0.8% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

-1.2%

Cash Flow

Operating Cash Flow

$82M

Free Cash Flow

$72M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$3.6B

Stockholders' Equity

$351M

Cash & Equivalents

$303M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$529M	$519M	+1.8%
Gross Profit	$199M	$134M	+48.6%
Operating Income	$29M	$2M	+1071.0%
Net Income	-$4M	-$9M	+52.8%

Revenue Segments

Generics Segment

$347M66%

Amneal Specialty Pharma Segment

$93M18%

Av K A R E Segment

$89M17%